TP53 and urinary bladder cancer: MDM2 overexpression has been found in some bladder cancer cells and contributes to doxorubicin resistance in bladder cancer, which could be a confounding factor to conclude that doxorubicin would be a suitable drug to target tumors with mutant TP53 (Shiina et al., 1999; Smith et al., 2003).